Idera Pharmaceuticals and XOMA Find Paths to Financial Growth

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Two stocks that investors gained confidence in on Wednesday are both getting attention from stockholders on recent news announcements. Both the companies may become a topic of discussion involving a potential buyout as a result of the positive financial and investment news. Investors are awaiting future updates that will occur over the next several weeks to determine whether today’s news will spurn a rise in the price of the stocks.

RDI Initiates Coverage:

Idera Pharmaceuticals
Inc. https://ub.rdinvesting.com/news/?ticker=IDRA

XOMA Corporation https://ub.rdinvesting.com/news/?ticker=XOMA

Idera Pharmaceuticals stock rose by $0.40 a share on Wednesday to close at $2.49, up more than 19%. Several reasons were attributed to the stock’s rise. First, JMP Securities of the JMP Group issued an “outperform” for the stock today as its initial rating. Its assigned target price for the stock is $8 per share. The second reason is the investor optimism for the company as it will present two of its hot candidates, at the American Association for Cancer Research meeting on April 1st – 5th. Two presentations for its lead candidate cancer drug, IMO-2125 are scheduled for the early morning of April 5th. Consensus of analysts has called for “buy” rating on the stock with average target price of $5.00, according to The Wall Street Journal. The Company has reported a profit of $0.8 million or $0.01 a share on revenue of $15.3 million for the fourth quarter of 2016 as compared to loss of $12 million or $0.1 a share on a revenue of $190,000 reported in the same quarter in the prior year. Jump in the revenue in the last quarter was primarily due to the Vivelix agreement, signed in November 2016. The company has seen its share price gain more than 75 percent over the last 60 days, and the presentation may further boost investor’s confidence in the IMO-2125 protocol.

Access RDI’s Idera Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=IDRA

At Wednesday’s close, XOMA Corporation found its stock scoot up $0.70 per share on Wednesday, to close at $6.045. The 13 percent increase was fueled by news that the company had fully prepaid its capital debt to Hercules Technology Growth, and it will reduce its general operating expenses while strengthening the overall balance sheet. This step introduces the company’s new business strategy, as the company has now decreased its debt by 39 percent or by $16.7 million in past three months. During the month of February, XOMA has funded itself with $25 million worth of registered offering of common stocks and convertible stocks to BVF Partners and also appointed Mr. Matthew Perry, President of BVF Partners to XOMA’s board of directors. Two weeks ago, some XOMA investors were surprised at the uptick in the stock price, with no apparent reason connected to it. After hours trading saw a slight retreat in the price of the stock.

Access RDI’s XOMA Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=XOMA

Our Actionable Research on Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and XOMA Corporation (NASDAQ: XOMA) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458004